FDA Announces New Director for Center of Biological Assessment and Research
The Food and Drug Administration has chosen a new director for the center that deals with vaccination disorders and other biological products. Dr. Vinay Prasad, a vocal critic of the agency’s steps, has been selected for the role. Prasad will replace Dr. Peter Marks, who played a key role in the introduction of Operation Warp Speed, the Trump administration’s efforts to accelerate the development of vaccines during the COVID-19 pandemic.
Background on Dr. Prasad
Dr. Prasad has been a long-time critic of the FDA, particularly with regards to the emergency authorization of COVID-19 vaccine boosters. He has stated that the agency was "either incompetent or corrupt" to approve a booster without clinical, randomized data. Prasad has also been critical of Dr. Marks, calling him "one of the most dangerous, pro-pharma regulatory officials of the 21st century" and a "mediocre academic".
Prasad’s Views on Vaccination
Prasad has expressed concerns about the COVID-19 vaccine, stating that it is "absurd" that the US still offers COVID vaccinations to young children. He has also warned that changes to the vaccine could lead to decreased effectiveness and safety. Prasad has called for new randomized clinical studies to be conducted before approving future updates to COVID shots.
Previous Controversies
During the pandemic, Prasad was accused of spreading misinformation about COVID-19 vaccines, along with Dr. Tracy Høeg. Despite this, Høeg now works for the FDA as a special assistant to Commissioner Dr. Martin Makary. Prasad has also been critical of vaccination mandates and has called for the Moderna vaccine to be banned for men under 40.
Reaction to Prasad’s Appointment
Commissioner Makary has praised Prasad’s "long and respected history in medicine" and stated that he "brings a tremendous set of skills, energy, and expertise to the FDA". Prasad’s appointment comes at a time when the FDA is considering whether to approve annual updates for COVID-19 vaccines in the fall. Officials have the option of requesting new randomized studies to be conducted before approving future updates to COVID shots.
